Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $20,260.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $10.13, for a total value of $20,260.00. Following the completion of the sale, the president now directly owns 2,827,018 shares of the company’s stock, valued at approximately $28,637,692.34. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Songjiang Ma also recently made the following trade(s):

• On Monday, March 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $12.09, for a total transaction of $24,180.00.
• On Friday, March 14th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.31, for a total transaction of $24,620.00.
• On Wednesday, March 12th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.74, for a total transaction of $23,480.00.
• On Monday, March 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.14, for a total transaction of $20,280.00.
• On Friday, March 7th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.25, for a total value of $20,500.00.
• On Monday, February 10th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.90, for a total value of $23,800.00.
• On Tuesday, February 4th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.62, for a total value of $23,240.00.
• On Wednesday, January 29th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.43, for a total value of $22,860.00.
• On Monday, January 27th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.18, for a total transaction of $22,360.00.
• On Thursday, January 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.49, for a total transaction of $20,980.00.

Gyre Therapeutics Stock Down 5.0 %

Gyre Therapeutics stock traded down $0.51 during midday trading on Friday, hitting $9.71. 261,173 shares of the company were exchanged, compared to its average volume of 80,987. The business has a fifty day simple moving average of $11.31 and a two-hundred day simple moving average of $12.23. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $19.00.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Monday, March 17th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.04 by ($0.03). The company had revenue of $27.87 million during the quarter, compared to analysts’ expectations of $23.50 million. Gyre Therapeutics had a negative return on equity of 118.43% and a negative net margin of 84.57%.

Wall Street Analysts Forecast Growth

Separately, Noble Financial began coverage on shares of Gyre Therapeutics in a research report on Tuesday, March 11th. They set an “outperform” rating for the company.

Institutional Trading of Gyre Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GYRE. SBI Securities Co. Ltd. acquired a new position in shares of Gyre Therapeutics in the fourth quarter worth about $1,225,000. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 392.2% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after purchasing an additional 90,557 shares during the period. Geode Capital Management LLC boosted its position in Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock worth $3,808,000 after purchasing an additional 43,840 shares in the last quarter. Advantage Alpha Capital Partners LP acquired a new stake in Gyre Therapeutics in the third quarter valued at approximately $334,000. Finally, Northern Trust Corp increased its position in shares of Gyre Therapeutics by 9.1% in the fourth quarter. Northern Trust Corp now owns 103,382 shares of the company’s stock valued at $1,251,000 after buying an additional 8,624 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.